protocolSection identificationModule nctId: NCT06311214, orgStudyIdInfo id: NCI-2024-01903, secondaryIdInfos id: NCI-2024-01903, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 10397, type: OTHER, domain: University of Texas MD Anderson Cancer Center LAO, secondaryIdInfos id: 10397, type: OTHER, domain: CTEP, secondaryIdInfos id: UM1CA186688, type: NIH, link: https://reporter.nih.gov/quickSearch/UM1CA186688, briefTitle: Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-21, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins and that may have spread from where they first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or to other places in the body (metastatic). Precision medicine is a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, or treat disease in a way that is tailored to the patient. ADCs such as sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan are monoclonal antibodies attached to biologically active drugs and are a form of targeted therapy. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab attaches to a protein called Trop-2 on the surface of tumor cells and delivers govitecan to kill them. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. Trastuzumab deruxtecan is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Personalized treatment with sacituzumab govitecan, enfortumab vedotin, or trastuzumab deruxtecan may be an effective treatment option for patients with advanced or metastatic solid tumors that screen positive for high expression of Trop-2, nectin-4, or HER2, respectively., conditionsModule conditions: Advanced Malignant Solid Neoplasm, conditions: Metastatic Malignant Solid Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Echocardiography, interventions name: Electronic Health Record Review, interventions name: Enfortumab Vedotin, interventions name: Immunohistochemistry Staining Method, interventions name: Magnetic Resonance Imaging, interventions name: Multigated Acquisition Scan, interventions name: Sacituzumab Govitecan, interventions name: Trastuzumab Deruxtecan, outcomesModule primaryOutcomes measure: Frequency of high protein expression in patients with high ribonucleic acid (RNA) expression of each antibody-drug conjugate target (screening protocol), primaryOutcomes measure: Objective response rate (treatment cohorts), secondaryOutcomes measure: Frequency that patients with high RNA and immunohistochemistry target expression receive cohort treatment on study (screening protocol), secondaryOutcomes measure: Progression free survival (treatment cohorts), secondaryOutcomes measure: Overall survival (treatment cohorts), secondaryOutcomes measure: Time to progression (treatment cohorts), secondaryOutcomes measure: Incidence of adverse events (treatment cohorts), secondaryOutcomes measure: RNA expression of targets of interest (TOIs) (treatment cohorts), secondaryOutcomes measure: Temporal tumor heterogeneity (treatment cohorts), secondaryOutcomes measure: Potential predictive biomarkers and other molecular features (treatment cohorts), secondaryOutcomes measure: Pharmacodynamic changes in the tumor and microenvironment (treatment cohorts), otherOutcomes measure: Mechanisms of acquired resistance (treatment cohorts), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False